| |

Unleashing the Immune System: How ONCOS-102 Enhances Mesothelioma Therapy

ByHolly Zink
Unleashing the Immune System: How ONCOS-102 Enhances Mesothelioma Therapy

An international team of scientists looked at adding a special kind of virus called ONCOS-102 to chemotherapy drugs. They found that adding ONCOS-102 can help mesothelioma patients live a bit longer during treatment.

Mesothelioma is an aggressive cancer caused by asbestos exposure. Treatment for this disease can include surgery, radiation, and chemotherapy.

The Promising Treatment Partnership

ONCOS-102 is a type of virus that can help the body’s immune system attack cancer cells. Scientists wanted to see if using ONCOS-102 with chemotherapy could make this treatment work better.

The current FDA-approved chemotherapy drugs for mesothelioma are pemetrexed with cisplatin. These drugs target rapidly growing cancer cells, but they can also affect healthy cells that grow rapidly such as blood cells.

To test ONCOS-102 with standard chemotherapy, they recruited 31 patients with mesothelioma. Some of these patients got ONCOS-102 along with chemotherapy. While others got only chemotherapy. The scientists were mainly interested in whether using ONCOS-102 with chemotherapy was safe for patients. They also looked at how long the patients lived, how fast the cancer grew, and how the immune system responded.

How ONCOS-102 Enhances Mesothelioma Therapy

The most common side effects were anemia. This is where you do not have enough red blood cells. And neutropenia, where you do not have enough white blood cells. These side effects were more common in the group that got ONCOS-102. But no one had to stop the treatment because of them.

The scientists did not see a big difference in how well the treatments worked. But, patients who had not had chemotherapy before and got ONCOS-102 lived a bit longer. They also noticed that ONCOS-102 seemed to make the environment around the tumor more ready for the immune system to fight the cancer. This was linked to better survival at month 18 post-treatment.

The scientists determined that when used with chemotherapy, ONCOS-102 was safe for patients with mesothelioma. With more research, scientists can find out how to use ONCOS-102 to make the area around the tumor more friendly to the immune system. This could be linked to better survival rates.

Source

Ponce S, Cedrés S, Ricordel C, et al. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. J Immunother Cancer. 2023;11(9):e007552. doi:10.1136/jitc-2023-007552. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476122/

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…